Distinct neuroanatomical correlates of neuropsychiatric symptoms in the three main forms of genetic frontotemporal dementia in the GENFI Cohort by L. Sellami et al.
Journal of Alzheimer’s Disease 65 (2018) 147–163
DOI 10.3233/JAD-180053
IOS Press
147
Distinct Neuroanatomical Correlates
of Neuropsychiatric Symptoms in the Three
Main Forms of Genetic Frontotemporal
Dementia in the GENFI Cohort
Leila Sellamim,1, Martina Bocchettaa,1, Mario Masellisf , David M. Casha,b, Katrina M. Dicka,
John van Swietenc, Barbara Borronid, Daniela Galimbertie, Maria Carmela Tartagliag,
James B. Roweh, Caroline Graffi,j, Fabrizio Tagliavinik, Giovanni Frisonil, Elizabeth Fingern,
Alexandre de Mendonc¸ao, Sandro Sorbip,q, Jason D. Warrena, Jonathan D. Rohrera,2
and Robert Jr. Laforcem,2,∗ on behalf of the Genetic FTD Initiative, GENFI3
aDepartment of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology,
Queen Square, London, UK
bCentre for Medical Image Computing, UCL, UK
cErasmus Medical Center, Rotterdam, Netherlands
dUniversity of Brescia, Brescia, Italy
eDepartment of Pathophysiology and Transplantation, “Dino Ferrari” Center, University of Milan, Fondazione
Ca´ Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
fCognitive Neurology Research Unit, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Research
Program, Sunnybrook Research Institute; Department of Medicine, University of Toronto, Toronto, ON, Canada
gTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada
hUniversity of Cambridge, Cambridge, UK
iKarolinska Institutet, Stockholm, Sweden; Department NVS, Center for Alzheimer Research, Division
of Neurogeriatrics, Sweden
jDepartment of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden
kIstituto Neurologico Carlo Besta, Milan, Italy
lIRCCS San Giovanni di Dio Fatebenefratelli Brescia, Italy
mClinique Interdisciplinaire de Me´moire (CIME), Universite´ Laval, QC, Canada
nUniversity of Western Ontario, ON, Canada
oFaculdade de Medicina, Universidade de Lisboa, Portugal
pDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University
of Florence, Florence, Italy
qIRCCS Don Carlo Gnocchi, Florence, Italy
Accepted 16 June 2018
1These authors contributed equally to this work.
2Joint senior authors.
3List of consortium members in Supplementary Material.
∗Correspondence to: Dr. Robert Jr. Laforce, Clinique Inter-
disciplinaire de Me´moire (CIME), De´partement des Sciences
Neurologiques, CHU de Que´bec; Faculte´ de me´decine, Univer-
site´ Laval, Que´bec, Canada. 1401, 18ie`me rue, Que´bec G1J 1Z4,
Canada. Tel.: +1 418 649 5980; Fax: +1 418 649 5981; E-mail:
robert.laforce@fmed.ulaval.ca.
ISSN 1387-2877/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
148 L. Sellami et al. / Correlates of Psychiatric Symptoms in Genetic FTD
Abstract.
Background: The overlap between frontotemporal dementia (FTD) and primary psychiatric disorders has been brought
to light by reports of prominent neuropsychiatric symptoms (NPS) in FTD-related genetic mutations, particularly among
C9orf72 and GRN carriers. It has been recently demonstrated that early neuroanatomical changes in genetic FTD may be
different across the major disease-causing mutations.
Objective: We aimed to identify whether NPS could be driven by distinct structural correlates.
Methods: One hundred and sixty-seven mutation carriers (75 GRN, 60 C9orf72, and 32 MAPT) were included from the
Genetic FTD Initiative (GENFI) study, a large international cohort of genetic FTD. Neuropsychiatric symptoms including
delusions, hallucinations (visual, auditory, and tactile), depression, and anxiety were investigated using a structured interview.
Voxel-based morphometry was performed to identify neuroanatomical correlates of NPS.
Results: Psychotic symptoms correlated mainly with grey matter (GM) atrophy in the anterior insula, left thalamus, cerebel-
lum, and cortical regions including frontal, parietal, and occipital lobes in GRN mutations carriers. GM atrophy in posterior
structures of the default-mode network was associated with anxiety in the GRN group. Delusions in C9orf72 expansion
carriers were mainly associated with left frontal cortical atrophy. Cerebellar atrophy was found to be correlated only with
anxiety in C9orf72 carriers. NPS in the MAPT group were mainly associated with volume loss in the temporal lobe.
Conclusion: Neuroanatomical correlates of NPS appear to be distinct across the main forms of genetic FTD. Overall, our
findings support overlapping brain structural changes between FTD and primary psychiatric disorders.
Keywords: Frontotemporal dementia, genetics, magnetic resonance imaging, neuropsychiatry
INTRODUCTION
Frontotemporal dementia (FTD) is the second most
common cause of young-onset dementia. It is a highly
heritable disease with an autosomal dominant mode
of inheritance being found in around a third of cases
[1, 2]. Mutations in three main genes have been identi-
fied in familial FTD: microtubule associated protein
tau (MAPT), progranulin (GRN), and chromosome
9 open reading frame 72 (C9orf72) [3]. Among
neurodegenerative dementias, FTD often mimics pri-
mary psychiatric conditions. Indeed, patients with
FTD are more likely to receive a prior inaccurate
psychiatric diagnosis [4].
The most common subtype, namely behavioral
variant FTD (bvFTD), is characterized by apathy, loss
of empathy, perseverative and compulsive behavior,
disinhibition, and hyperorality [5]. These symptoms
often lead to bvFTD being misdiagnosed with either
late onset depression or obsessive-compulsive and
impulse-control disorders. Other neuropsychiatric
symptoms (NPS) such as delusions or hallucina-
tions are frequently present in FTD with a third of
patients having psychotic symptoms in neuropatho-
logically confirmed cases [6]. Although FTD may
mimic late-onset schizophrenia or bipolar spectrum
disorders in some cases, psychosis and mood disor-
ders are not considered clinical hallmarks of bvFTD
[7] and are not included within current diagnostic
criteria.
Recent genetic advances in the understanding of
familial forms of FTD have rekindled interest in the
borderlands between FTD and psychiatric disorders,
by revealing a high frequency of NPS in genetic
FTD, particularly among C9orf72 and GRN mutation
carriers [8–10]. NPS sometimes emerge many years
prior to dementia onset and appear to have different
phenomenology across FTD-related mutations [10,
11]. Cross sectional results from the Genetic FTD
Initiative (GENFI) have previously shown evidence
for neuroanatomical changes in presymptomatic FTD
mutation carriers [12, 13]. The insula has been shown
to be the earliest affected region in genetic FTD, a
key hub in the salience network which has been con-
sidered as an influential model in several psychiatric
disorders such as schizophrenia [14]. To our knowl-
edge, no study has been carried out to date, which
assesses the correlation between NPS and neurostruc-
tural changes across the three main genes associated
with FTD. Characterizing the neural correlates across
familial FTD would provide important insight into
the distinctive structures involved in the neuropsychi-
atric phenotype in FTD and therefore enable further
understanding of the pathophysiological substrate
and neurobiological basis of NPS. The pattern of
brain atrophy could ultimately guide targeted genetic
testing particularly in cases of atypical and over-
lapping FTD/neuropsychiatric presentations. In this
study, we applied voxel-based morphometry (VBM)
to a large international cohort of presymptomatic
and symptomatic carriers of FTD-related mutations.
We hypothesized that neuroanatomical correlates of
NPS would be distinct between the different forms of
genetic FTD and would bring evidence of overlapping
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brain structural changes with primary psychiatric
disorders.
MATERIALS AND METHODS
Participants
We assessed the structural correlates of NPS in
cases with genetic FTD enrolled within the GENFI
cohort [12]. GENFI is a multicenter study, which
during the first phase consisted of 13 research sites,
in the UK, Italy, Portugal, the Netherlands, Swe-
den, and Canada. Participants recruited to GENFI
were either known carriers of a pathogenic mutation
in MAPT, GRN, or C9orf72, or at risk of carry-
ing a mutation because a first-degree relative was a
known symptomatic carrier. Between January 2012
and April 2015, 365 participants were recruited into
GENFI, of which 205 were mutation carriers. Of
the 205 mutation carriers, 167 participants had T1-
weighted MRI scans suitable for VBM analysis.
All subjects underwent a standard clinical assess-
ment consisting of a family history, past medical
history, neuropsychological assessment, and physical
examination. NPS including delusions, hallucina-
tions, depression, and anxiety were also questioned.
This was performed with the participant and carer,
using a scale scored from 0 to 3. The NPS scale
used in the current study was adapted from the Neu-
ropsychiatric Inventory [15]. The NPS scale includes
6 questions that cover the domains of psychosis and
affective disorders. Each of the 6 individual symptom
domains (visual, auditory and tactile hallucina-
tions, delusions, depression, and anxiety) contains
a survey question that reflects the main suggestive
features. Initial answer to each domain is “present”
or “absent”. If “absent”, the domain is scored 0. If
“present”, the severity is rated on a four-point scale
(0.5 = questionable/very mild, 1 = mild, 2 = moderate
and 3 = severe). Both symptomatic and presymp-
tomatic mutation carriers were included in the present
study. In the context of this study, presymptomatic
status refers to subjects who are carriers of a
pathogenic mutation in MAPT, GRN, or C9orf72,
without meeting the international consensus criteria
for bvFTD, PPA or FTD-MND [5]. All participants
from the GENFI cohort, that were assessed for neu-
ropsychiatric symptoms and that had a suitable MRI
scans for VBM, were included in the current study.
Local ethics committees at each site approved the
study and all participants provided written informed
consent.
MRI acquisition and VBM analysis
Participants underwent volumetric T1-weighted
MRI, according to the GENFI imaging protocol. Sites
used different types of scanners: Siemens Trio 3T,
Siemens Skyra 3T, Siemens 1.5T, Phillips 3T, General
Electric (GE) 1.5T and GE 3T. Scan protocols were
designed at the outset of the study to ensure adequate
matching between scanners and image quality con-
trol. Voxel-based morphometry was performed using
Statistical Parametric Mapping (SPM) 12 software,
version 6906 (http://www.fil.ion.ucl.ac.uk/spm), run-
ning under Matlab R2012a (Math Works, USA).
T1-weighted images were normalized and seg-
mented into grey matter, white matter (WM), and
cerebrospinal fluid (CSF) probability maps, by
using standard procedures and the fast-diffeomorphic
image registration algorithm (DARTEL) [16]. GM
segments were affine transformed into the Montreal
Neurological Institute (MNI) space, modulated and
smoothed using a Gaussian kernel with 6 mm full-
width at half maximum before analysis. Finally, a
mask was applied as reported in [17]. Study-specific
templates were created based on the subjects included
in the specific analysis. At each stage, all segmen-
tations were reviewed visually. Total intracranial
volume (TIV) was calculated using SPM [18].
Statistical analysis
Differences in demographic and clinical charac-
teristics were assessed using a Chi-squared test, and
one-way ANOVA (with post hoc Tukey test) using
SPSS software version 22 (SPSS Inc, Chicago, Illi-
nois, USA). The significance threshold was set at
0.05. Correlations were calculated with the Spear-
man’s rank coefficient (rS).
Regarding the VBM analysis, the preprocessed
GM tissue maps were fitted to a multiple regression
model to identify the negative correlation between
GM density and neuropsychiatric symptoms, which
were measured by the NPS scale (score from 0 to
3). The analyses were run separately for each genetic
group (GRN, MAPT, C9orf72) and for each symp-
tom (visual hallucinations, auditory hallucinations,
tactile hallucinations, delusions, depression and anxi-
ety). Age, gender, TIV, and scanner type were entered
as nuisance covariates. The uncorrected statistical
threshold was set at p < 0.001, with a minimum
cluster size of 10 voxels. The Family-Wise Error
(FWE) and False Discovery Rate (FDR) for multiple
comparisons correction were set at 0.05.
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RESULTS
Among the 167 mutation carriers, 45% had a muta-
tion in the GRN gene, 36% in the C9orf72, and 19%
in the MAPT. Participants consisted of 122 presymp-
tomatic (63 GRN, 37 C9orf72, and 22 MAPT) and 45
symptomatic (12 GRN, 23 C9orf72, and 10 MAPT)
carriers (see Table 1). Individuals with MAPT muta-
tions were significantly younger (mean age 44.3
years versus 52.1 and 51.3 years in C9orf72 and
GRN, respectively; p = 0.013). According to the Fron-
totemporal Dementia Rating Scale (FRS) [19], in
the symptomatic group: three participants (1 GRN,
1 C9orf72, and 1 MAPT) were mildly impaired, three
(1 GRN, 1 C9orf72, and 1 MAPT) were moderately
impaired, 18 (3 GRN, 12 C9orf72, and 3 MAPT)
were severely impaired, 15 (5 GRN, 7 C9orf72, and
3 MAPT) were very severely impaired and 5 (2
GRN, 1 C9orf72, and 2 MAPT) were profoundly
impaired; FRS was not available for one patient.
There was no significant correlation between mean
NPS score and disease severity in symptomatic car-
riers (rS = 0.21, p = 0.15). There were no significant
differences between the three genetic groups in terms
of severity scores nor frequency of hallucinations
(visual, auditory and tactile), delusions, depression
and anxiety (see Table 2). Distribution of NPS among
presymptomatic and symptomatic carriers is dis-
played in Supplementary Table 1.
Statistical parametric maps showing correlations
between each NPS score and GM density in the three
genetic groups are reported in Figs. 1 to 6. For visual
hallucinations (Fig. 1), in the GRN group, we found
significant negative correlations between the clinical
score and GM in a large network of areas including
mainly the parietal lobe (left superior parietal lobule
and left angular gyrus), inferior occipital gyrus, left
thalamus and left middle frontal gyrus (these clus-
ters remained significant after FWE correction for
multiple comparisons p < 0.05), with further areas in
the cerebellum and temporal lobe (Supplementary
Table 2). In the C9orf72 group, we identified a signifi-
cant negative correlation with GM in the parietal lobe
(left superior parietal lobule and left angular gyrus)
and left occipital pole (Supplementary Table 3). In
the MAPT group, visual hallucinations score corre-
lated with GM in the precentral gyrus, left lingual
gyrus, right fusiform gyrus, and left angular gyrus
(Supplementary Table 4). In the GRN group, auditory
hallucinations (Fig. 2) were associated with the left
Table 1
Demographics
GRN (n = 75) C9orf72 (n = 60) MAPT (n = 32) p
Gender, female, n (%) 48 (64%) 31 (51.7%) 16 (50%) 0.24
Right-handed, n (%) 66 (88%) 57 (95%) 29 (90.6%) 0.53
Age (y) 51.3 (11.4) 52.1 (14.2) 44.3 (12) 0.01*
Education (y) 13.4 (3.5) 13.5 (3.7) 12.9 (3.8) 0.75
Clinical status
Symptomatic, n (%) 12 (16%) 23 (38%) 10 (31%) 0.14
Presymptomatic, n (%) 63 (84%) 37 (62%) 22 (68%) 0.48
Data are No (%) or mean (SD). *One-way ANOVA p value < 0.05, post hoc p = 0.027 for MAPT versus GRN and p = 0.015
for MAPT versus C9orf72.
Table 2
Frequency and severity of neuropsychiatric symptoms (NPS) in the genetic groups
NPS GRN (n = 75) C9orf72 (n = 60) MAPT (n = 32) p
Visual hallucinations Frequency 3 (4%) 4 (7%) 2 (6%) 0.77
Severity 0.05 (0.28;0–2) 0.15 (0.57; 0–3) 0.05 (0.19; 0–1) 0.31
Auditory hallucinations Frequency 3 (4%) 3 (5%) 2 (6%) 0.88
Severity 0.05 (0.28; 0–2) 0.09 (0.46; 0–3) 0.07 (0.19; 0–1) 0.76
Tactile hallucinations Frequency 3 (4%) 2 (3%) 1 (3%) 0.96
Severity 0.05 (0.28; 0–2) 0.04 (0.26; 0–2) 0.03 (0.17; 0–1) 0.91
Delusions Frequency 4 (5%) 7 (12%) 3 (9%) 0.40
Severity 0.07 (0.30; 0–2) 0.21 (0.65; 0–3) 0.13 (0.42; 0–2) 0.23
Depression Frequency 16 (21%) 18 (30%) 6 (19%) 0.37
Severity 0.24 (0.52; 0–2) 0.33 (0.58; 0–2) 0.23 (0.55; 0–2) 0.57
Anxiety Frequency 12 (16%) 17 (28%) 9 (28%) 0.17
Severity 0.18 (0.46; 0–2) 0.35 (0.62; 0–2) 0.34 (0.64; 0–2) 0.16
Frequency is reported as No.(%). Severity was assessed using a NPS Scale: 0 = absent, 0.5 = very mild, 1 = mild,
2 = moderate, 3 = severe, data are mean score (SD and range are given in brackets).
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Fig. 1. VBM analysis showing areas of significant correlation between the presence and severity of visual hallucinations and GM density
across the FTD genetic groups. Statistical parametric maps were thresholded at p < 0.001 uncorrected and rendered on a study-specific
T1-weighted MRI template in MNI space. Analyses were adjusted for age, gender, total intracranial volume, and scanner type. The color
bar indicates the Z-scores.
anterior insula, left thalamus, frontal lobe, temporal
lobe, and the cerebellum when correcting for mul-
tiple comparisons (Supplementary Table 5). In the
C9orf72 group, a significant negative correlation was
found in the left middle frontal gyrus (Supplementary
Table 6). In the MAPT group, the auditory halluci-
nations score was related to GM atrophy in the right
angular gyrus (Supplementary Table 7). Areas related
to tactile hallucinations (Fig. 3) in the GRN group
(Supplementary Table 8) were similar to those seen
in auditory hallucinations. In the C9orf72 group, we
found a significant negative correlation in the inferior
frontal gyrus and posterior cingulate gyrus (Supple-
mentary Table 9). Significant areas were seen in the
MAPT group within the frontal lobe and left lingual
gyrus (Supplementary Table 10).
As displayed in Fig. 4, GRN mutation carri-
ers showed a significant association between the
delusions score and GM atrophy mainly in the
left thalamus and left anterior insula when cor-
recting for multiple comparisons (Supplementary
Table 11). In the C9orf72 group, we found a sig-
nificant correlation between delusions and GM in
the left middle and superior frontal gyri (Supple-
mentary Table 12). In the MAPT group, the most
significant areas for delusions were in the temporal
lobe (left middle temporal gyrus and left hippocam-
pus), frontal lobe, parietal lobe, left subcallosal area,
left anterior insula, and fusiform gyrus when cor-
recting for multiple comparisons (Supplementary
Table 13).
For the depression score (Fig. 5), we found signif-
icant correlations within the GRN group, with GM
in the frontal lobe, right subcallosal area, bilateral
anterior insula, left middle cingulate, right cere-
bellum, temporal lobe, and right middle occipital
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Fig. 2. VBM analysis showing areas of significant correlation between the presence and severity of auditory hallucinations and GM density
across the FTD genetic groups. Statistical parametric maps were thresholded at p < 0.001 uncorrected and rendered on a study-specific
T1-weighted MRI template in MNI space. Analyses were adjusted for age, gender, total intracranial volume, and scanner type. The color
bar indicates the Z-scores.
gyrus (these clusters survived after FDR correction)
(Supplementary Table 14). In C9orf72 expansion
carriers, the depression score was correlated with
GM atrophy in the parietal lobe (left precuneus and
superior parietal lobule) and left superior frontal
gyrus (Supplementary Table 15). In the MAPT group,
we identified significant negative correlations with
GM in the left postcentral gyrus, temporal lobe,
right fusiform gyrus, right lingual gyrus, superior
motor cortex, and left cerebellum (Supplementary
Table 16).
Finally, for the anxiety score (Fig. 6), GRN muta-
tion carriers showed significant correlations with GM
atrophy in areas including the frontal lobe, left ante-
rior insula, left precuneus, left posterior cingulate,
temporal lobe, left caudate, left superior occipital
gyrus, and bilateral cerebellum when correcting for
multiple comparisons (Supplementary Table 17). In
the C9orf72 group, we found significant correla-
tions in the inferior frontal gyrus, left cerebellum,
left fusiform gyrus and right superior temporal gyrus
(Supplementary Table 18). In the MAPT group, the
main significant areas were in the temporo-parietal
and frontal lobes as well as bilateral cuneus (Supple-
mentary Table 19).
Table 3 summarizes the regional grey matter cor-
relates of NPS from the VBM analysis.
DISCUSSION
Our findings highlight the involvement of
widespread cortical and subcortical brain structures,
as part of large-scale networks, in the occurrence of
NPS in FTD mutation carriers. These results sug-
gest a strong association of psychotic symptoms with
GM atrophy in the anterior insula in GRN mutation
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Fig. 3. VBM analysis showing areas of significant correlation between the presence and severity of tactile hallucinations and GM density
across the FTD genetic groups. Statistical parametric maps were thresholded at p < 0.001 uncorrected and rendered on a study-specific
T1-weighted MRI template in MNI space. Analyses were adjusted for age, gender, total intracranial volume, and scanner type. The color
bar indicates the Z-scores.
carriers and, to a lesser extent, in MAPT carriers.
Moreover, the GRN group showed particular involve-
ment of the left thalamus, left middle frontal gyrus,
and cerebellum in the emergence of psychosis. In
the C9orf72 group, psychotic symptoms were mainly
associated with changes in the frontal cortex, whereas
the MAPT group involved the temporal lobe and
angular gyri. The presence of mood disorders was
mostly associated with GM atrophy in frontal-insular
cortex, in addition to precuneus and posterior cingu-
late, in the GRN group. Parietal and frontal cortices as
well as cerebellum alterations correlated with mood
disorders in C9orf72 carriers, whereas in MAPT car-
riers, depression and anxiety were mainly associated
with the temporo-parietal cortex.
The involvement of the insula in the emergence
of psychotic symptoms in GRN mutations carriers
supports the aberrant salience hypothesis previously
reported in mental disorders [20, 21]. The insula is
critical for the regulation of a number of affective
and cognitive functions, including body-self con-
sciousness and subjective emotional experience. It is
thought to integrate multisensory inputs and coordi-
nate the allocation of the brain’s attentional resources
to the most relevant stimuli [22]. The anterior part of
the insula, which is especially correlated to NPS in
our study, was shown to be particularly specialized
for interoception, subjective feelings, and emotional
awareness [23]. Psychotic symptoms including delu-
sions and all sensory modalities of hallucinations
were also significantly associated with greater GM
atrophy in the left thalamus within the GRN group.
The disturbances of thalamo-cortical networks were
suggested to contribute to the emergence of psychotic
symptoms in schizophrenia [24].
The involvement of large-scale networks in the
emergence of NPS in FTD is also reflected by
the significant association of NPS with cerebellar
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Fig. 4. VBM analysis showing areas of significant correlation between the presence and severity of delusions and GM density across the
FTD genetic groups. Statistical parametric maps were thresholded at p < 0.001 uncorrected and rendered on a study-specific T1-weighted
MRI template in MNI space. Analyses were adjusted for age, gender, total intracranial volume, and scanner type. The color bar indicates the
Z-scores.
alteration in the GRN group. A growing body of evi-
dence arising from functional magnetic resonance
imaging (fMRI) implicates cortico-cerebellar con-
nectivity loops in the pathophysiology of primary
psychiatric conditions [25]. Schmahmann et al. con-
sidered the psychosis spectrum as an integral part
of the cerebellar cognitive affective syndrome and
linked it to damage of the fastigial nucleus and
the vermis, defined as “the limbic cerebellum” [26,
27]. Our results showed evidence of frontal involve-
ment in delusions among C9orf72 expansion carriers
which is inconsistent with a previous study sug-
gesting an association between delusions and GM
atrophy in the precuneus [28]. Limited data are avail-
able on the specific content of delusional thoughts in
C9orf72 carriers. Authors have reported odd somatic
complaints, somatoform delusions and body image
distortion [11, 29]. This observation is supported
by the evidence of altered body scheme percep-
tion and processing among patients with C9orf72
expansion [30]. Interestingly, the superior and middle
frontal gyri along with inferior frontal and poste-
rior cingulate gyri, which correlated respectively with
delusions and tactile hallucinations in our C9orf72
group, have previously been considered as part of
the neural correlates of somatoform disorders [31].
The MAPT group was mainly distinguished by the
involvement of the left temporal lobe in delusional
symptoms, in line with previous reports suggesting a
predominant temporal alteration in MAPT mutation
carriers [12, 32]. This is also consistent with previ-
ous studies that reported an association between GM
atrophy in temporo-limbic areas and vulnerability to
psychosis [33].
As expected, visual hallucinations were mainly
characterized by the involvement of the visual cortex
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Fig. 5. VBM analysis showing areas of significant correlation between the presence and severity of depression and GM density across the
FTD genetic groups. Statistical parametric maps were thresholded at p < 0.001 uncorrected and rendered on a study-specific T1-weighted
MRI template in MNI space. Analyses were adjusted for age, gender, total intracranial volume, and scanner type. The color bar indicates the
Z-scores.
including the occipito-parietal and occipito-temporal
regions across the three genetic mutations, consistent
with previous studies which demonstrated structural
and functional disconnectivity within visual pro-
cessing areas in hallucinatory experiences [34]. The
correlation of visual hallucinations with GM in the
left angular gyrus was shared by all genetic groups.
The left angular gyrus alteration has previously been
considered as a structural substrate in schizophrenia
[35], but its role in the emergence of visual halluci-
nations remains unexplored. Based on our results, we
might speculate that the angular gyrus, as part of the
heteromodal parietal association cortex, plays pre-
sumably an important role in the psychopathology
of visual hallucinations in genetic FTD. The GRN
group was characterized by a significant correlation
between thalamic atrophy, particularly posteriorly
(including the pulvinar) and visual hallucinations.
Vulnerability to visual hallucinations as a result of
thalamic dysfunction has been reported in neurode-
generative diseases such as Lewy body dementia
(LBD) [36]. Interestingly visual hallucinations have
previously been reported as an important distinctive
feature in GRN carriers which could sometimes even
present with a LBD-like phenotype [10]. Atrophy of
the frontal lobe has also been found to correlate with
visual hallucinations in both GRN and MAPT groups.
Several studies have shown visual hallucinations to
be linked to frontal structures, as reflected in pre-
vious correlational analyses performed in LBD and
Parkinson’s disease [37].
Mood disorders in the GRN group were mainly
related to a fronto-insular-cerebellar alteration. We
also noted particular involvement of the posterior
portions of the default-mode network (DMN) (pre-
cuneus and posterior cingulate cortex) in anxiety and
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Fig. 6. VBM analysis showing areas of significant correlation between the presence and severity of anxiety and GM density across the FTD
genetic groups. Statistical parametric maps were thresholded at p < 0.001 uncorrected and rendered on a study-specific T1-weighted MRI
template in MNI space. Analyses were adjusted for age, gender, total intracranial volume, and scanner type. The color bar indicates the
Z-scores.
of left hippocampus in both anxiety and depression.
Left precuneus atrophy has also been found to be
correlated to depression in C9orf72 expansion car-
riers. This study supports previous findings of the
role of DMN alterations in depression and anxiety
disorders [38–40]. The MAPT group was character-
ized by the involvement of right temporo-occipital
areas in depression and left temporo-parietal regions
in anxiety. This is in line with the prominence of
mood disorders in neurodegenerative disease pre-
senting with a major alteration of posterior cortical
areas as illustrated by posterior cortical atrophy
[41, 42]. Disparate findings for depression could
be reconciled through its conceptualization as a
constellation of symptoms related to several psy-
chopathological mechanisms (self-related mental
representation, referential judgments, negative self-
focused thoughts . . . ), which can be underpinned
by different structural and neurobiological dys-
functions [43, 44]. Though the structural models
underlying the psychopathology of depression can
be distinct, they may involve overlapping functional
networks and neurobiological systems including
serotoninergic, noradrenergic and dopaminergic
tracts.
Anxiety was previously reported as a prominent
feature in C9orf72 expansion carriers [45]. It is inter-
esting to note that, despite a recognized pattern of
cerebellar involvement in the C9orf72 expansion
[46], its atrophy has proved to be only related to anx-
iety in our study, but not to psychosis as previously
reported [47]. Variability in findings between studies
may be due to several factors, including sample size,
different neuroimaging techniques, and medication.
Overall, we found the most significant results in the
GRN group.
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The lack of specific identification of each symp-
tom’s nature through the use of the NPS scale instead
of a full psychiatric questionnaire is a limitation.
Psychotic symptoms are a multidimensional phe-
nomenon, which is difficult to deconstruct through
a clinical scale, therefore caution should be taken
in interpreting the results. For instance, odd somatic
complaints in C9orf72 expansion carriers may be
mistaken for anxiety disorders. Further studies should
be performed based on detailed psychiatric assess-
ment, including expanded items of valid psychiatric
rating scales, to improve the detection of subtle NPS
and better refine their phenomenology. Connectivity-
based neuroanatomical methods will be required in
order to provide a better understanding of the under-
lying structural substrates and networks dynamics of
psychotic symptoms.
Despite these limitations, to our knowledge, this
is the first study to investigate the neuroanatom-
ical correlates of a wide range of NPS in the
three main mutations responsible for genetic FTD.
Moreover, our findings, taking into account the
presymptomatic phase of the disease, support that
NPS may be considered as prodromal hallmarks of
early neurodegeneration, within the scope of mild
behavioral impairment (MBI). The concept of MBI
was developed as a potential pre-dementia stage. New
diagnostic criteria and a standardized scale to mea-
sure MBI have recently emerged [48, 49]. Affective
dysregulation and abnormal perception/thought con-
tent were stated as MBI subcategories. A previous
study showed that MBI patients had a high conversion
rate to dementia (71.5%), mainly evolvement to FTD
[50]. Therefore, the study of NPS offers the opportu-
nity of early diagnosis and could allow measurement
of future disease-modifying preventive strategies in
at-risk individuals.
Conclusions
Our findings demonstrated that structural corre-
lates of NPS may be distinct in the three main
forms of genetic FTD, which could theoretically
explain the differences observed in neuropsychiatric
phenomenology between genetic subtypes. Addi-
tionally, our study supported that clinical overlap
between FTD and primary psychiatric conditions
may be mediated by the alteration of common struc-
tures involved in large-scale networks. Future studies
should consider detailed neuropsychiatric assessment
and perform a multimodal neuroimaging approach to
further explore the functional networks and neural
substrates of specific NPS.
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